| Wellness and the role of comorbidities in multiple sclerosis BP Moss, MR Rensel, CM Hersh Neurotherapeutics 14 (4), 999-1017, 2017 | 83 | 2017 |
| Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up CM Hersh, TE Love, A Bandyopadhyay, S Cohn, C Hara-Cleaver, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 3 (3 …, 2017 | 73 | 2017 |
| Updates and advances in multiple sclerosis neurotherapeutics M Amin, CM Hersh Neurodegenerative disease management 13 (1), 47-70, 2023 | 67 | 2023 |
| Harnessing real-world data to inform decision-making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) EM Mowry, RA Bermel, JR Williams, TLS Benzinger, C De Moor, E Fisher, ... Frontiers in neurology 11, 632, 2020 | 65 | 2020 |
| Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised … JF Foley, G Defer, LZ Ryerson, JA Cohen, DL Arnold, H Butzkueven, ... The Lancet Neurology 21 (7), 608-619, 2022 | 64 | 2022 |
| Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol D Ontaneda, EC Tallantyre, PC Raza, SM Planchon, K Nakamura, ... Contemporary Clinical Trials 95, 106009, 2020 | 41 | 2020 |
| Experience with fingolimod in clinical practice CM Hersh, C Hara-Cleaver, RA Rudick, JA Cohen, RA Bermel, ... International Journal of Neuroscience 125 (9), 678-685, 2015 | 35 | 2015 |
| Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers B Vollmer, D Ontaneda, A Bandyopadhyay, S Cohn, K Nair, S Sillau, ... Neurology: Clinical Practice 8 (4), 292-301, 2018 | 29 | 2018 |
| Alemtuzumab for the treatment of relapsing–remitting multiple sclerosis CM Hersh, JA Cohen Immunotherapy 6 (3), 249-259, 2014 | 27 | 2014 |
| How the COVID-19 pandemic has changed multiple sclerosis clinical practice: results of a nationwide provider survey EH Morrison, K Michtich, CM Hersh Multiple Sclerosis and Related Disorders 51, 102913, 2021 | 25 | 2021 |
| Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60 LH Hua, CM Hersh, F Tian, EM Mowry, KC Fitzgerald Multiple sclerosis and related disorders 47, 102637, 2021 | 21 | 2021 |
| Associations of sNfL with clinico‐radiological measures in a large MS population ES Sotirchos, KC Fitzgerald, CM Singh, MD Smith, M Reyes‐Mantilla, ... Annals of Clinical and Translational Neurology 10 (1), 84-97, 2023 | 20 | 2023 |
| Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment C Hersh, A Rae-Grant Therapeutic Advances in Neurological Disorders 5 (4), 199-204, 2012 | 20 | 2012 |
| The impact of price reductions after loss of exclusivity in a cost-effectiveness analysis: fingolimod versus interferon beta-1a for the treatment of relapsing-remitting … LH Hua, CM Hersh, P Morten, J Kusel, F Lin, J Cave, S Varga, V Herrera, ... Journal of managed care & specialty pharmacy 25 (4), 490-498, 2019 | 18 | 2019 |
| Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up B Vollmer, D Ontaneda, H Harris, K Nair, RA Bermel, JR Corboy, RJ Fox, ... Journal of the Neurological Sciences 407, 116498, 2019 | 17 | 2019 |
| Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions JA Cohen, RA Bermel, CI Grossman, CM Hersh, M Hyland, EM Mowry, ... Multiple Sclerosis Journal 28 (7), 1131-1137, 2022 | 15 | 2022 |
| Optic neuropathy and stroke secondary to invasive aspergillus in an immunocompetent patient CM Hersh, S John, A Subei, MA Willis, GS Kosmorsky, RA Prayson, ... Journal of Neuro-Ophthalmology 36 (4), 404-407, 2016 | 14 | 2016 |
| Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS CM Hersh, B Kieseier, C Moor, DM Miller, D Campagnolo, JR Williams, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 7 (2 …, 2021 | 13 | 2021 |
| Effect of switching from natalizumab to moderate-vs high-efficacy DMT in clinical practice CM Hersh, H Harris, D Conway, LH Hua Neurology: Clinical Practice 10 (6), e53-e65, 2020 | 13 | 2020 |
| Multiple sclerosis progression discussion tool usability and usefulness in clinical practice: cross-sectional, web-based survey T Ziemssen, G Giovannoni, E Alvarez, V Bhan, C Hersh, O Hoffmann, ... Journal of Medical Internet Research 23 (10), e29558, 2021 | 11 | 2021 |
